Usher Institute, University of Edinburgh Medical School, Edinburgh, UK.
University of St Andrews School of Medicine, Medical and Biological Sciences, St Andrews, UK.
Lancet Public Health. 2021 Aug;6(8):e587-e597. doi: 10.1016/S2468-2667(21)00107-9. Epub 2021 Jun 22.
A systematic understanding of how multimorbidity has been constructed and measured is unavailable. This review aimed to examine the definition and measurement of multimorbidity in peer-reviewed studies internationally.
We systematically reviewed studies on multimorbidity, via a search of nine bibliographic databases (Ovid [PsycINFO, Embase, Global Health, and MEDLINE], Web of Science, the Cochrane Library, CINAHL Plus, Scopus, and ProQuest Dissertations & Theses Global), from inception to Jan 21, 2020. Reference lists and tracked citations of retrieved articles were hand-searched. Eligible studies were full-text articles measuring multimorbidity for any purpose in community, primary care, care home, or hospital populations receiving a non-specialist service. Abstracts, qualitative research, and case series were excluded. Two reviewers independently reviewed the retrieved studies with conflicts resolved by discussion or a third reviewer, and a single researcher extracted data from published papers. To assess our objectives of how multimorbidity has been measured and examine variation in the chronic conditions included (in terms of number and type), we used descriptive analysis (frequencies, cross-tabulation, and negative binomial regression) to summarise the characteristics of multimorbidity studies and measures (study setting, source of morbidity data, study population, primary study purpose, and multimorbidity measure type). This systematic review is registered with PROSPERO, CRD420201724090.
566 studies were included in our review, of which 206 (36·4%) did not report a reference definition for multimorbidity and 73 (12·9%) did not report the conditions their measure included. The number of conditions included in measures ranged from two to 285 (median 17 [IQR 11-23). 452 (79·9%) studies reported types of condition within a single multimorbidity measure; most included at least one cardiovascular condition (441 [97·6%] of 452 studies), metabolic and endocrine condition (440 [97·3%]), respiratory condition (422 [93·4%]), musculoskeletal condition (396 [87·6%]), or mental health condition (355 [78·5%]) in their measure of multimorbidity. Chronic infections (123 [27·2%]), haematological conditions (110 [24·3%]), ear, nose, and throat conditions (107 [23·7%]), skin conditions (70 [15·5%]), oral conditions (19 [4·2%]), and congenital conditions (14 [3·1%]) were uncommonly included. Only eight individual conditions were included by more than half of studies in the multimorbidity measure used (diabetes, stroke, cancer, chronic obstructive pulmonary disease, hypertension, coronary heart disease, chronic kidney disease, and heart failure), with individual mental health conditions under-represented. Of the 566 studies, 419 were rated to be of moderate risk of bias, 107 of high risk of bias, and 40 of low risk of bias according to the Effective Public Health Practice Project quality assessment tool.
Measurement of multimorbidity is poorly reported and highly variable. Consistent reporting of measure definitions should be required by journals, and consensus studies are needed to define core and study-dependent conditions to include in measures of multimorbidity.
Health Data Research UK.
目前我们对于如何构建和衡量多病共存(multimorbidity)还没有系统的认识。本研究旨在对国际同行评审研究中多病共存的定义和测量方法进行综述。
我们通过对九个文献数据库(Ovid [PsycINFO、Embase、全球健康、MEDLINE]、Web of Science、Cochrane 图书馆、CINAHL Plus、Scopus 和 ProQuest 学位论文和全文数据库全球版)进行了系统性检索,查找了从创建到 2020 年 1 月 21 日有关多病共存的研究,以评估国际上对多病共存的定义和测量方法。检索到的文章参考文献列表和跟踪引用的参考文献都进行了手工检索。纳入的研究为在社区、初级保健、护理院或接受非专科服务的医院人群中,为任何目的测量多病共存的全文文章。摘要、定性研究和病例系列研究被排除在外。两名评审员独立对检索到的研究进行了评审,如果存在分歧,则通过讨论或由第三名评审员解决,然后由一名研究员从已发表的论文中提取数据。为了评估我们的目标,即了解多病共存的测量方法,并研究所包括的慢性疾病的变化(在数量和类型方面),我们使用描述性分析(频率、交叉表和负二项式回归)来总结多病共存研究和测量方法的特征(研究环境、发病数据来源、研究人群、主要研究目的和多病共存测量方法类型)。本系统评价已在 PROSPERO 上注册,注册号为 CRD420201724090。
本研究共纳入 566 项研究,其中 206 项(36.4%)未报告多病共存的参考定义,73 项(12.9%)未报告其测量方法中包含的疾病。测量中包含的疾病数量从两个到 285 个不等(中位数 17 [IQR 11-23])。452 项(79.9%)研究报告了单一多病共存测量方法中的疾病类型;大多数研究包括至少一种心血管疾病(441 [97.6%])、代谢和内分泌疾病(440 [97.3%])、呼吸疾病(422 [93.4%])、肌肉骨骼疾病(396 [87.6%])或精神健康疾病(355 [78.5%])。慢性感染(123 [27.2%])、血液疾病(110 [24.3%])、耳鼻喉疾病(107 [23.7%])、皮肤疾病(70 [15.5%])、口腔疾病(19 [4.2%])和先天疾病(14 [3.1%])不太常见。在使用的多病共存测量方法中,只有 8 种疾病被超过一半的研究纳入(糖尿病、中风、癌症、慢性阻塞性肺疾病、高血压、冠心病、慢性肾脏病和心力衰竭),而个别精神健康疾病则代表性不足。根据有效公共卫生实践项目质量评估工具,566 项研究中,419 项被评为中度偏倚风险,107 项为高度偏倚风险,40 项为低偏倚风险。
多病共存的测量方法报告较差且高度可变。期刊应要求报告测量定义,需要进行共识研究以定义核心和依赖于研究的疾病,以纳入多病共存的测量中。
英国健康数据研究。